Top

Published in:

01-07-2006

Galectin 7 (p53-Induced Gene 1): A New Prognostic Predictor of Recurrence and Survival in Stage IV Hypopharyngeal Cancer

Authors: Sven Saussez, MD, Diana-Raluca Cucu, Christine Decaestecker, PhD, Dominique Chevalier, MD, Herbert Kaltner, Vet MD, Sabine André, PhD, Agnes Wacreniez, MD, Gérard Toubeau, PhD, Isabelle Camby, PhD, Hans-Joachim Gabius, PhD, Robert Kiss, PhD

Published in: Annals of Surgical Oncology | Issue 7/2006

Abstract

Background

Eighty percent of hypopharyngeal squamous cell carcinoma patients have advanced stages (III and IV) of the disease, and biological markers are required to predict high-risk head and neck squamous cell carcinoma patients in need of highly aggressive treatments after surgery to improve the survival rate. We analyzed the potential prognostic value of galectin 7 in a series of 81 stage IV hypopharyngeal SCCs because galectin 7 is an emerging marker involved in the epidermal development of pluristratified epithelia and in epidermal cell migration.

Methods

The immunohistochemical expression of galectin 7 was determined on a series of 81 stage IV hypopharyngeal SCCs and was compared with that of galectins 1 and 3.

Results

High levels of galectin 7 expression were associated with rapid recurrence rates and dismal prognoses in these 81 stage IV hypopharyngeal SCCs, a feature not observed with galectin 3 and one observed weakly, if at all, with galectin 1.

Conclusions

These data suggest that the immunohistochemical determination of galectin 7 expression in the case of high-risk hypopharyngeal cancers is a meaningful tool to identify patients who should benefit from aggressive postsurgical adjuvant therapy after surgery, including not only radiotherapy, but also chemotherapy.

Hunter KD, Parkinson EK, Harrison PR. Profiling early head and neck cancer. Nat Rev Cancer 2005; 5:127–35PubMedCrossRef

Grandis JR, Pietenpol JA, Greeberger JS, et al. Head and neck cancer: meeting summary and research opportunities. Cancer Res 2004; 64:8126–9PubMedCrossRef

Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937–44PubMedCrossRef

Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945–52PubMedCrossRef

Schantz SP, Harrison LB, Forastiere AA. Tumors of the nasal cavity and paranasal sinuses, nasopharynx, oral cavity, and oropharynx. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Vol 1, 5th ed. Philadelphia: Lippincott, 1997; 741–847

Shah JP. Head and Neck Surgery. 2nd ed. New York: Mosby-Wolfe, 1996

Myers JN. The use of biological therapy in cancer of the head and neck. Curr Probl Cancer 1999; 23:106–34PubMedCrossRef

Liu FT, Rabinovich GA. Galectins as modulators of tumor progression. Nat Rev Cancer 2005; 5:29–41PubMedCrossRef

Gabius HJ, Siebert HC, André S, et al. Chemical biology of the sugar code. Chembiochem 2004; 5:740–64PubMedCrossRef

10.

Danguy A, Camby I, Kiss R. Galectins and cancer. Biochim Biophys Acta 2002; 1572:285–93PubMed

11.

Saussez S, Kiss R. Galectin-7. Review. Cell Mol Life Sci 2006; 63:686–97PubMedCrossRef

12.

Polyak K, Xia Y, Zweier JL, et al. A model for p53-induced apoptosis. Nature 1997; 389:300–5PubMedCrossRef

13.

Timmons PM, Colnot C, Cail I, et al. Expression of galectin-7 during epithelial development coincides with the onset of stratification. Int J Dev Biol 1999; 43:229–35PubMed

14.

Lahm H, André S, Hoeflich A, et al. Tumor galectinology: insight into the complex network of a family of endogenous lectins. Glycoconj J 2004; 20:227–38PubMedCrossRef

15.

Kopitz J, André S, von Reitzenstein C, et al. Homodimeric galectin-7 (p53-induced gene 1) is a negative growth regulator for human neuroblastoma cells. Oncogene 2003; 22:6277–88PubMedCrossRef

16.

Saussez S, Marchant H, Nagy N, et al. Quantitative glycohistochemistry defines new prognostic markers for cancers of the oral cavity. Cancer 1998; 82:252–60PubMedCrossRef

17.

Gillenwater A, Xu XC, El-Naggar AK, et al. Expression of galectins in head and neck squamous cell carcinoma. Head Neck 1996; 18:422–32PubMedCrossRef

18.

Gillenwater A, Xu XC, Estrov Y, et al. Modulation of galectin-1 content in human head and neck squamous carcinoma cells by sodium butyrate. Int J Cancer 1998; 75:217–24PubMedCrossRef

19.

Delorge S, Saussez S, Pelc P, et al. Correlation of galectin-3/galectin-3-binding sites with low differentiation status in head and neck squamous cell carcinomas. Otolaryngol Head Neck Surg 2000; 122:834–41PubMed

20.

Plzak J, Smetana K Jr, Hrdlickova E, et al. Expression of galectin-3 reactive ligands in squamous cancer and normal epithelial cells as a marker of differentiation. Int J Oncol 2001; 19:59–64PubMed

21.

Choufani G, Nagy N, Saussez S, et al. The levels of expression of galectin-1, galectin-3, and the Thomsen-Friedenreich antigen and their binding sites decrease as clinical aggressiveness increases in head and neck cancers. Cancer 1999; 86:2353–63PubMedCrossRef

22.

Honjo Y, Inohara H, Akahani S, et al. Expression of cytoplasmic galectin-3 as a prognostic marker in tongue carcinoma. Clin Cancer Res 2000; 6:4635–40PubMed

23.

Piantelli M, Iacobelli S, Almaddri G, et al. Lack of expression of galectin-3 is associated with a poor outcome in node-negative patients with laryngeal squamous-cell carcinoma. J Clin Oncol 2002; 20:3850–6PubMedCrossRef

24.

Plzak J, Betka J, Smetana K Jr, et al. Galectin-3—an emerging prognostic indicator in advanced head and neck carcinoma. Eur J Cancer 2004; 40:2324–30PubMedCrossRef

25.

Chen J, He QY, Yuen APW, et al. Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorigenesis. Proteomics 2004; 4:2465–75PubMedCrossRef

26.

Kuwabara I, Kuwabara Y, Yang RY, et al. Galectin-7 (PIG1) exhibits pro-apoptotic function through JNK activation and mitochondrial cytochrome C release. J Biol Chem 2002; 277:3487–97PubMedCrossRef

27.

Ueda S, Kuwabara I, Liu FT. Suppression of tumor growth by galectin-7 gene transfer. Cancer Res 2004; 64:5672–6PubMedCrossRef

28.

Sobin LH, Wittekin DC. TNM Classification of Malignant Tumours UICC International Union Against Cancer. 6th ed. West Sussex, UK: Wiley BR, 2002

29.

Hyams VJ, Batsakis JG, Michaels L, eds. Tumors of the Upper Respiratory Tract and Ear. Atlas of Tumor Pathology. Washington, DC: Armed Forces Institute of Pathology, 1988

30.

Gabius HJ. Influence of type of linkage and spacer on the interaction of β-galactoside-binding proteins with immobilized affinity ligands. Anal Biochem 1990; 189:91–4PubMedCrossRef

31.

André S, Kojima S, Yamazaki N, et al. Galectins-1 and -3 and their ligands in tumor biology. J Cancer Res Clin Oncol 1999; 125:461–74PubMedCrossRef

32.

André S, Pieters RJ, Vrasidas I, et al. Wedgelike glycodendrimers as inhibitors of binding of mammalian galectins to glycoproteins, lactose maxiclusters, and cell surface glycoconjugates. Chembiochem 2001; 2:822–30PubMedCrossRef

33.

Camby I, Belot N, Rorive S, et al. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 2001; 11:12–26PubMedCrossRef

34.

Rorive S, Eddafali B, Fernandez S, et al. Changes in galectin-7 and cytokeratin-19 expression during the progression of malignancy in thyroid tumors: diagnostic and biological implications. Mod Pathol 2002; 15:1294–301PubMedCrossRef

35.

Nagy N, Legendre H, Engels O, et al. Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer 2003; 97:1849–58PubMedCrossRef

36.

Decaestecker C, Camby I, Remmelink M, et al. Decision tree induction: a useful tool for assisted diagnosis and prognosis in tumor pathology. Lab Invest 1997; 76:799–808PubMed

37.

Bernerd F, Sarasin A, Magnaldo T. Galectin-7 overexpression is associated with the apoptotic process in UVB-induced sunburn keratinocytes. Proc Natl Acad Sci U S A 1999; 96:11329–34PubMedCrossRef

38.

Demers M, Magnaldo T, St-Pierre Y. A novel function for galectin-7: promoting tumorigenesis by up-regulating MMP-9 gene expression. Cancer Res 2005; 65:5205–10PubMedCrossRef

39.

O-Charoenrat P, Wongkajornsilp A, Rhys-Evans PH, et al. Signaling pathways required for matrix metalloproteinases-9 induction by betacellulin in head-and-neck squamous carcinoma cells. Int J Cancer 2004; 111:174–83PubMedCrossRef

40.

Wiegand S, Dunne AA, Muller HH, et al. Metaanalysis of the significance of matrix metalloproteinases for lymph node disease in patients with head and neck squamous cell carcinoma. Cancer 2005; 104:94–100PubMedCrossRef

41.

Lu J, Pei H, Kaeck M, et al. Gene expression changes associated with chemically induced rat mammary carcinogenesis. Mol Carcinogenesis 1997; 20:204–15CrossRef

42.

Moisan S, Demers M, Mercier J, et al. Upregulation of galectin-7 in murine lymphoma is associated with progression toward an aggressive phenotype. Leukemia 2003; 17:751–9PubMedCrossRef

43.

Laird PW, Jaenisch R. The role of DNA methylation in cancer genetic and epigenetics. Annu Rev Genet 1996; 30:441–64PubMedCrossRef

44.

Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000; 16:168–74PubMedCrossRef

45.

Pogribny IP, Pogribna M, Hristman JK, et al. Single-site methylation within the p53 promoter region reduces gene expression in a reporter gene construct: possible in vivo relevance during tumorigenesis. Cancer Res 2000; 60:588–94PubMed

46.

Itzkowitz SH. Galectins: multipurpose carbohydrate-binding proteins implicated in tumor biology. Gastroenterology 1997; 113:2003–5PubMed

Title: Galectin 7 (p53-Induced Gene 1): A New Prognostic Predictor of Recurrence and Survival in Stage IV Hypopharyngeal Cancer
Authors: Sven Saussez, MD
Diana-Raluca Cucu
Christine Decaestecker, PhD
Dominique Chevalier, MD
Herbert Kaltner, Vet MD
Sabine André, PhD
Agnes Wacreniez, MD
Gérard Toubeau, PhD
Isabelle Camby, PhD
Hans-Joachim Gabius, PhD
Robert Kiss, PhD
Publication date: 01-07-2006
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 7/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/ASO.2006.08.033

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Galectin 7 (p53-Induced Gene 1): A New Prognostic Predictor of Recurrence and Survival in Stage IV Hypopharyngeal Cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2006

Initial Outcomes for Patients Treated on the American Society of Breast Surgeons MammoSite Clinical Trial for Ductal Carcinoma-In-Situ of the Breast

Ethnic Disparities in Breast Cancer Management Among Asian Americans and Pacific Islanders

PIK3CA and TFRC Located in 3q Are New Prognostic Factors in Esophageal Squamous Cell Carcinoma

Prognostic Significance of Molecular Staging Study of Sentinel Lymph Nodes by Reverse Transcriptase-Polymerase Chain Reaction for Tyrosinase in Melanoma Patients

The Prognostic Importance of Sentinel Lymph Node Biopsy in Thin Melanoma

Three–Axillary Lymph Node Sampling for the Prediction of Nonsentinel Node Metastases in Breast Cancer Patients With Sentinel Node Metastases